1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The potential to preserve lean mass during GLP-1 induced weight loss is crucial for improving long-term health outcomes and metabolic function in individuals with obesity. Preventing muscle loss can enhance strength, …
If successful, this pilot study could reveal a novel therapeutic application for tirzepatide, potentially offering significant relief for post-menopausal women with obesity suffering from vasomotor symptoms. Beyond sy…
As this is a recruiting clinical trial, specific results are not yet available; however, the study aims to demonstrate significant improvements in key health metrics. Researchers hypothesize that preoperative tirzepat…
This study highlights Tirzepatide's potential as a powerful tool for long-term weight management, particularly for individuals who have already achieved initial success with lifestyle interventions. The ability to not…
The successful integration of tirzepatide with automated insulin delivery could represent a paradigm shift in Type 1 Diabetes management, offering a novel strategy to improve glucose control beyond current capabilitie…
The provided research record is a study protocol description from ClinicalTrials.gov and, as such, does not contain specific efficacy or safety results from the trial. The study, NCT06445075, is listed as COMPLETED, i…
The study aimed to demonstrate that tirzepatide significantly impacts food intake and modulates brain activity in areas associated with appetite and reward. While specific quantitative results are not detailed in this…
This planned study is significant because it aims to explore a novel therapeutic avenue for a highly complex patient population: individuals with obesity and chronic kidney failure. If Tirzepatide demonstrates a favor…
If successful, this study could represent a significant advancement in the treatment of adolescent obesity and its associated health burdens. The potential for tirzepatide to not only reduce weight but also improve ca…
Successfully demonstrating the feasibility and efficacy of tirzepatide for weight loss in early-stage HR+/Her2- breast cancer patients could represent a significant advancement in supportive cancer care. Effective wei…
This Phase 3 trial is highly significant as it directly compares Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, against a standard rapid-acting insulin, insulin lispro (U100), in a challenging patient populatio…
This study is critically important as it will provide a head-to-head comparison of the most effective current treatments for obesity, offering invaluable data for clinical decision-making. If Semaglutide or Tirzepatid…
The findings of this study are crucial for enhancing patient safety during surgical procedures for individuals on GLP-1/GIP agonists. If standard fasting guidelines prove insufficient, it could lead to revised pre-ope…
The potential for tirzepatide, a drug primarily known for its efficacy in type 2 diabetes and weight management, to treat Hidradenitis Suppurativa is highly significant. If successful, this study could repurpose an ex…
This pilot trial is crucial as it explores a novel therapeutic avenue for Alcohol Use Disorder (AUD), a condition with significant unmet medical needs. If tirzepatide, a GLP-1/GIP receptor agonist primarily used for d…
The bold challenge of weight regain after successful initial weight loss significantly impacts long-term health outcomes for individuals with obesity. If Retatrutide proves effective in maintaining weight reduction, i…
This trial is crucial because retatrutide, a novel triple agonist targeting GIP, GLP-1, and glucagon receptors, holds significant promise for treating obesity and its complex comorbidities. If successful, it could off…
Ensuring bioequivalence and safety across different drug delivery devices is a critical step in pharmaceutical development and patient access. If the Test Device proves to be bioequivalent and equally safe, it could f…
The initiation of this large-scale clinical trial for Retatrutide is a pivotal step towards addressing the interconnected epidemics of Type 2 Diabetes and obesity with a single, highly potent therapeutic agent. If suc…
If successful, this trial could represent a significant advancement for patients with Type 2 Diabetes and renal impairment, a group with limited treatment options and high unmet medical need. Retatrutide could offer a…
The findings from this trial are highly anticipated, as obesity is a major driver of osteoarthritis progression and a significant barrier to effective management. Retatrutide's ability to induce substantial weight los…
The successful modulation of calorie intake and energy expenditure by LY3437943 could represent a significant advancement in obesity treatment. If LY3437943 demonstrates a favorable impact on these parameters, it coul…
If successful, this study could demonstrate a significant cardio-renal protective effect of Retatrutide beyond its known weight-loss benefits. This would be a crucial advancement, as current treatments for obesity oft…
The SYNERGY-OUTCOMES study holds immense significance as it addresses a critical unmet medical need for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition without approved pharmacologic trea…
If successful, this Phase 2 study could demonstrate that LY3437943 is a highly effective and well-tolerated treatment for obesity and overweight with comorbidities, potentially offering a new therapeutic avenue. The e…
A favorable drug-drug interaction profile is a critical factor for the successful development of any new medication, particularly for chronic conditions like obesity where patients often take multiple concomitant drug…
This Phase 3b trial is pivotal for optimizing Retatrutide's clinical utility by identifying the most effective and well-tolerated dosing strategies for long-term use. Understanding the nuances of dose escalation can s…
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…
Understanding how kidney function affects LY3437943's pharmacokinetics is crucial for ensuring patient safety and guiding appropriate dosing strategies across diverse populations. This data is essential for developing…
This head-to-head Phase 3 trial is critically important because it directly compares retatrutide, a potential best-in-class GLP-1/GIP/Glucagon receptor triple-agonist, against semaglutide, a leading GLP-1 receptor ago…
If successful, this Phase 3b trial could establish Retatrutide as a highly effective and safe treatment option for obesity and overweight, potentially offering superior weight loss outcomes compared to existing therap…
Preventing muscle loss during significant weight reduction is critical for long-term health outcomes, as preserved muscle mass contributes to better metabolic function, strength, and overall quality of life. If succes…
This study provides compelling evidence for the robust efficacy and favorable safety profile of Mazdutide 9 mg as a potent new treatment for obesity, specifically in Chinese adults. These findings are critical for adv…
This study provides crucial real-world evidence suggesting that GLP-1 RA initiation significantly impacts TSH levels in patients on levothyroxine, often necessitating dose adjustments. The key implication is that clin…